Movano Health (Nasdaq: MOVE) has announced that it is actively addressing additional clarifying questions from the FDA regarding the medical aspects of its EvieMED Ring, as part of the final phase of the 510(k) application review process. The company had previously achieved a positive resolution after responding to initial FDA inquiries about the EvieMED's wellness features and metrics this summer.
John Mastrototaro, President and CEO of Movano Health, stated, "The FDA 510(k) clearance process is a rigorous one and we are pleased with the progress we continue to make. We are confident we can effectively address the follow up questions that the Agency has submitted, and we look forward to completing the final review of the EvieMED Ring."
EvieMED Ring Features
The EvieMED Ring is designed to provide medical device functionality through its pulse oximetry feature, as well as wellness metrics related to sleep, activity, and mood logging.
Direct-to-Consumer Sales
Separately, Movano Health announced the resumption of direct-to-consumer (D2C) orders for the Evie Ring on September 17, 2024. The company reports a positive initial response to product and operational improvements, including enhanced sleep, heart rate, and activity monitoring, expanded AI-generated personalized insights, and upgrades across manufacturing, logistics, and customer service, achieved through a fully organic marketing campaign.
About Movano Health
Movano Health, founded in 2018, is focused on developing healthcare solutions that bring medical-grade data to wearables. Their devices aim to capture a comprehensive picture of an individual's health data and translate it into personalized and intelligent insights.
